Important: this practice guideline applies to care provided to all individuals within the rochester area, including those who are members of a rochester area managed care plan
Approach to Adult Patient Unable to Maintain Nutrition
____________________________________________________________ ______________________
□ Weight Change □ Body Mass Index □ Lab Tests: albumin, prealbumin, cholesterol, lymphocyte count □ Hydration Status (skin turgor, heart rate, BUN/creatinine) □ Urine Output □ Other: ______________________________________________________________________ Comments about above factors: _____________________________________________________________________ _______________________________________________________________________________________________
Factors that Impede Ability to Take in Food
□ Physical Limitations □ Pain □ Visual Problems □ Chewing Problems: mouth, teeth, dentures □ Swallowing Problems: cough after/while eating, holding bolus, pocketing, position while eating or being fed □ Nausea/Vomiting □ Constipation □ Candidiasis □ Shortness of Breath □ Dementia, Depression, Anxiety □ Communication Problems □ Neurological Conditions □ Other: ______________________________________________________________________ Comments about above factors: ______________________________________________________________________ _______________________________________________________________________________________________
□ Stage of Illness : advanced or end stage illness □ ADL Score (please refer to Appendix G for Clinical Frailty Scale): current ____________ □ ADL Score: 1 month prior to admission ____________
□ Constipation/Fecal Impaction □ Other: ______________________________________________________________________ Comments about above factors: ______________________________________________________________________ _______________________________________________________________________________________________
□ Sedatives: lorazepam, clonazepam, etc. □ Antipsychotics: risperidone, quetiapine, aripiprazole, etc. □ Cholingerics for Alzheimer’s and other dementias: donepezil, galantamine, rivastigmine □ Anticholingerics: tolterodine, oxybutynin chloride □ GI irritants or anorexigencis: NSAIDs, COX IIs, bisphosphonates, opioids, digoxin, theophylline, antibiotics, iron, calcium, memantine, SSRIs □ Other: ______________________________________________________________________ Comments about medications: ________________________________________________________________________ ________________________________________________________________________________________________
Correctable Conditions Identified and Acted Upon and Additional Comments: ________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Evaluating Clinician: ________________________________________ _______________ ___________________
Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs. Approved April 2013. Next scheduled review by April 2015.
Langerhans cell histiocytosis: update for the pediatricianSheila Wand R. Maarten aDivision of Pediatric Hematology/Oncology,The Hospital for Sick Children, Toronto and UniversityLangerhans cell histiocytosis is the commonest of the histiocytic disorders. Owing toof Toronto, Toronto, Canada and bImmunology,Hematology/Oncology and Bone Marrow Transplant,the relative rarity of the condition, it
Rycoben SC for Sheep Introduction Frimley Business Park Frimley Camberley Surrey GU16 7SR 01276 694402 01276 694403 Presentation A creamy pink coloured aqueous suspension containing 2.5% w/v ricobendazole (albendazole oxide) for the treatment of sheep. Contains 1.8% w/v hydrated cobalt sulphate (equivalent to 3.77 mg of elemental cobalt/ml) and 0.19% w/v hydrated sodi